Krystal Biotech (NASDAQ:KRYS) Given Buy Rating at Chardan Capital

Krystal Biotech (NASDAQ:KRYS)‘s stock had its “buy” rating restated by research analysts at Chardan Capital in a report issued on Wednesday,Benzinga reports. They presently have a $212.00 price objective on the stock. Chardan Capital’s price target would indicate a potential upside of 31.82% from the company’s current price.

Several other research analysts have also recently weighed in on the stock. Stifel Nicolaus upped their price target on shares of Krystal Biotech from $204.00 to $220.00 and gave the stock a “buy” rating in a report on Wednesday, September 11th. HC Wainwright restated a “buy” rating and issued a $221.00 target price on shares of Krystal Biotech in a research note on Wednesday. Cantor Fitzgerald reiterated an “overweight” rating on shares of Krystal Biotech in a research report on Thursday, August 29th. William Blair raised Krystal Biotech to a “strong-buy” rating in a report on Friday, August 30th. Finally, Citigroup raised their target price on shares of Krystal Biotech from $204.00 to $206.00 and gave the company a “neutral” rating in a research note on Tuesday, November 5th. One analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, Krystal Biotech presently has a consensus rating of “Buy” and a consensus target price of $206.67.

Krystal Biotech Stock Up 2.7 %

Shares of KRYS opened at $160.83 on Wednesday. Krystal Biotech has a twelve month low of $107.50 and a twelve month high of $219.34. The stock has a market cap of $4.63 billion, a PE ratio of 90.86 and a beta of 0.80. The business’s 50-day moving average price is $180.46 and its 200-day moving average price is $185.00.

Krystal Biotech (NASDAQ:KRYS) last posted its earnings results on Monday, November 4th. The company reported $0.91 earnings per share for the quarter, topping analysts’ consensus estimates of $0.84 by $0.07. Krystal Biotech had a net margin of 21.68% and a return on equity of 7.54%. The business had revenue of $83.84 million for the quarter, compared to analyst estimates of $82.94 million. During the same quarter in the prior year, the firm posted ($0.67) EPS. Krystal Biotech’s revenue was up 879.9% on a year-over-year basis. Analysts expect that Krystal Biotech will post 2.97 earnings per share for the current fiscal year.

Insider Activity at Krystal Biotech

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the business’s stock in a transaction on Friday, December 13th. The shares were sold at an average price of $164.78, for a total value of $4,119,500.00. Following the completion of the sale, the insider now directly owns 1,475,882 shares of the company’s stock, valued at $243,195,835.96. The trade was a 1.67 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 14.10% of the stock is currently owned by insiders.

Institutional Trading of Krystal Biotech

A number of institutional investors have recently modified their holdings of KRYS. Key Financial Inc bought a new position in shares of Krystal Biotech during the second quarter valued at approximately $28,000. Blue Trust Inc. increased its position in Krystal Biotech by 2,328.6% during the 2nd quarter. Blue Trust Inc. now owns 170 shares of the company’s stock valued at $30,000 after purchasing an additional 163 shares during the period. Wilmington Savings Fund Society FSB bought a new position in Krystal Biotech in the 3rd quarter worth $40,000. Values First Advisors Inc. purchased a new stake in shares of Krystal Biotech in the 3rd quarter worth about $53,000. Finally, Quest Partners LLC purchased a new stake in shares of Krystal Biotech in the 2nd quarter worth about $71,000. 86.29% of the stock is currently owned by hedge funds and other institutional investors.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).